




**FORGOTTEN  
PEOPLE  
FORGOTTEN  
DISEASES**

**THE NEGLECTED TROPICAL DISEASES AND THEIR  
IMPACT ON GLOBAL HEALTH AND DEVELOPMENT**

**PETER J. HOTEZ, MD, PHD**

**THIRD EDITION**






FORGOTTEN  
**PEOPLE**  
FORGOTTEN  
**DISEASES**

**THE NEGLECTED TROPICAL DISEASES AND THEIR  
IMPACT ON GLOBAL HEALTH AND DEVELOPMENT**

**PETER J. HOTEZ, MD, PHD**

THIRD EDITION



# Table of Contents

[Cover](#)

[Title Page](#)

[Copyright](#)

[Dedication](#)

[Preface](#)

[Acknowledgments](#)

[Note](#)

[1 Introduction to the Neglected Tropical Diseases: the Ancient Afflictions of Stigma and Poverty](#)

[Notes](#)

[References](#)

[2 “The Unholy Trinity”: the Soil-Transmitted Helminth Infections Ascariasis, Trichuriasis, and Hookworm Infection](#)

[Notes](#)

[References](#)

[3 Schistosomiasis \(Snail Fever\) and the Food-borne Trematodiasis](#)

[Schistosomiasis](#)

[Food-borne Trematodiasis](#)

[Notes](#)

[References](#)

[4 Elephantiasis: Lymphatic Filariasis, Endemic Nonfilarial Elephantiasis \(Podoconiosis\), and Dracunculiasis \(Guinea Worm\)](#)

[LF](#)

[Podoconiosis \(Endemic Nonfilarial Elephantiasis\)](#)

[Dracunculiasis \(Guinea Worm Infection\)](#)

[Conclusions](#)

[Notes](#)

[References](#)

[5 The Blinding Neglected Tropical Diseases: Onchocerciasis \(River Blindness\) and Trachoma](#)

[Onchocerciasis](#)

[Trachoma](#)

[Notes](#)

[References](#)

[6 The Mycobacterial Infections: Buruli Ulcer and Leprosy](#)

[Buruli Ulcer](#)

[Leprosy](#)

[Notes](#)

[References](#)

[7 The Kinetoplastid Infections: Human African Trypanosomiasis \(Sleeping Sickness\), American Trypanosomiasis \(Chagas Disease\), and the Leishmaniasis](#)

[HAT](#)

[Chagas Disease \(American Trypanosomiasis\)](#)

[Leishmaniasis](#)

[Notes](#)

[References](#)

[8 The Urban Neglected Tropical Diseases: Leptospirosis, Dengue and Zika, and Rabies](#)

[Leptospirosis](#)

[Dengue fever \(break bone fever\) and Zika virus infection](#)

[Rabies](#)

[Summary](#)

[Notes](#)

[References](#)

## [9 The Neglected Tropical Diseases of North America](#)

[NTDs in the United States](#)

[NTDs in Texas](#)

[NTDs in Arctic Canada and Alaska](#)

[Summary of NTDs in the United States and the Arctic Region](#)

[NTDs in Mexico and the Caribbean](#)

[Conclusions](#)

[Notes](#)

[References](#)

## [10 Uniting to Combat Neglected Tropical Diseases, and a New WHO Roadmap \(2021-2030\)](#)

[Notes](#)

[References](#)

## [11 Future Trends in Control of Neglected Tropical Diseases and the Antipoverty Vaccines](#)

[Notes](#)

[References](#)

## [12 The Newest NTDs and a Plea to “Repair the World”](#)

[The Newest NTDs](#)

[Tikkun Olam](#)

[Notes](#)

[References](#)

## [Appendix: What Are the Neglected Tropical Diseases?](#)

[Index](#)

[About the Author](#)

[Other Titles from Peter J. Hotez](#)

[End User License Agreement](#)

## List of Tables

### Chapter 1

[Table 1.1 The MDGs](#)

[Table 1.2 The NTDs \(core group of 20\)<sup>a</sup>](#)

[Table 1.3 The WHO 20 NTDs ranked by prevalence<sup>a</sup>](#)

[Table 1.4 Major attributes of the NTDs](#)

[Table 1.5 Ranking of the “gang of four” by deaths and DALYs](#)

### Chapter 2

[Table 2.1 The “unholy trinity”](#)

### Chapter 3

[Table 3.1 The major human schistosomes](#)

### Chapter 4

[Table 4.1 Major filariae or filaria-like parasites of humans](#)

### Chapter 7

[Table 7.1 The major species of HAT and animal trypanosomiasis](#)

[Table 7.2 Simplified summary of the human leishmaniasis<sup>a</sup>](#)

### Chapter 9

[Table 9.1 Summary of the NTDs of the United States and the Arctic region<sup>a</sup>](#)

## Chapter 10

[Table 10.1 Ranking of the 10 most prevalent NTDs \(targeted by preventive ch...](#)

[Table 10.2 Summary of MDA programs for the most prevalent NTDs<sup>a</sup>](#)

## Chapter 11

[Table 11.1 Major PDPs for NTDs and related neglected diseases](#)

## Appendix

[Table 1 The major NTDs<sup>a</sup>](#)

# List of Illustrations

## Chapter 1

[Figure 1.1 Map of the world's coendemic NTDs. \(Drawn by Ashish Damania, Nati...](#)

[Figure 1.2 Disfiguring effects of the NTDs. \(Top\) Elephantiasis of the leg d...](#)

## Chapter 2

[Figure 2.1 Children \(left\) living outside the Brazilian village of Americani...](#)

[Figure 2.2 Prevalence of STH infections among school-age children in America...](#)

[Figure 2.3 The relationship between prevalence of hookworm and poverty. The ...](#)

[Figure 2.4 \(Left\) Little girl from Paraguay with severe \*Ascaris\* worm infecti...](#)

[Figure 2.5 Global distribution of human hookworm infection. \(From Global Bur...](#)



[Figure 2.6 Distribution of human hookworm infection in the American South at...](#)

[Figure 2.7 Life cycle of the hookworm \*N. americanus\*. \(From Hotez et al., 200...](#)

[Figure 2.8 \*Necator americanus\* \(hookworm\) L3 infectious larva. \(Photo courtes...](#)

[Figure 2.9 Severe hookworm disease. The child is both pale and edematous, th...](#)

[Figure 2.10 Jeca Tatu. Image from Weise K. 1924. \*Jéca Tatuzinho\*. Montei...](#)

[Figure 2.11 Proportion of children \(1 to 14 years of age\) by country requiri...](#)

### Chapter 3

[Figure 3.1 Distribution of schistosomiasis, worldwide. \(From Global Burden o...](#)

[Figure 3.2 Life cycle of human schistosomes. \(Modified from CDC-PHIL \[ID#341...](#)

[Figure 3.3 Spined eggs of \*S. haematobium\* \(top\) and \*S. mansoni\* \(bottom\). \(Im...](#)

[Figure 3.4 Children in Niger with hematuria. \(Photo courtesy of Juerg Utzin...](#)

### Chapter 4

[Figure 4.1 Prevalence of LF, worldwide. \(From Global Burden of Disease Colla...](#)

[Figure 4.2 Life cycle of \*W. bancrofti\*. \(Modified from CDC-PHIL \[ID#3425\]/Ale...](#)

[Figure 4.3 What do Stephen Hawking and Mao Zedong have in common? \(Hawking p...](#)

[Figure 4.4 Life cycle of the guinea worm. \(Modified from CDC-PHIL \[ID#3391\]/...](#)

[Figure 4.5 Clinical infection with guinea worm. \(Top\) Subcutaneous emergence...](#)

## Chapter 5

[Figure 5.1 Map of southern Sudan showing the Mankien study site. \(Reprinted ...](#)

[Figure 5.2 Distribution of onchocerciasis, worldwide. \(From Global Burden of...](#)

[Figure 5.3 Life cycle of \*O. volvulus\*. \(Modified from CDC-PHIL \[ID#3413\]/Alex...](#)

[Figure 5.4 A bronze study of a blind man led by a young boy \(R. T. Wallen\). ...](#)

[Figure 5.5 Distribution of trachoma, worldwide. \(From Global Burden of Disea...](#)

[Figure 5.6 Trachoma patient—a fifth-grade student—in Silti Zone, Ethiopia. ...](#)

## Chapter 6

[Figure 6.1 Distribution of Buruli ulcer, worldwide, 2010. \(© WHO. 2011. Acce...](#)

[Figure 6.2 Case of Buruli ulcer. \(Reproduced from World Health Organization....](#)

[Figure 6.3 National Hansen's Disease Center, Carville, LA. \(Patients' Recrea...](#)

[Figure 6.4 Bronze statue of Father Damien at the U.S. Capitol. \(See <https://...>](#)

[Figure 6.5 Disability caused by leprosy, worldwide. \(From Global Burden of D...](#)

[Figure 6.6 Drawing of \*M. leprae\* under the microscope and following staining....](#)

## Chapter 7

[Figure 7.1 Distribution of Gambian HAT \(\*T. b. gambiense\*\), worldwide, 2018. ...](#)

[Figure 7.2 Distribution of Rhodesian HAT \(\*T. b. rhodesiense\*\), worldwide, 201...](#)

[Figure 7.3 Photomicrograph of stained trypanosomes in the bloodstream. \(Imag...](#)

[Figure 7.4 Life cycle of human trypanosomes and HAT. \(Image from CDC-PHIL \[I...](#)

[Figure 7.5 Reproduction of J. E. Dutton's original watercolor drawing of \*T. ...\*](#)

[Figure 7.6 Distribution of Chagas disease, worldwide. \(From Global Burden of...](#)

[Figure 7.7 Triatomine bug, \*Rhodnius prolixus\*. \(Courtesy of Erwin Huebner, Un...](#)

[Figure 7.8 Life cycle of \*T. cruzi\* and Chagas disease. \(Image from CDC-PHIL \[...](#)

[Figure 7.9 Distribution of CL, worldwide, 2009. \(From Global Burden of Disea...](#)

[Figure 7.10 Distribution of VL, worldwide, 2009. \(From Global Burden of Dise...](#)

[Figure 7.11 Life cycle of human leishmaniasis infection. \(Image from CDC-PHI...](#)

[Figure 7.12 The “pizza-like” lesion of CL. \(Image from CDC-PHIL \[ID#352/CDC/...](#)

## Chapter 8

[Figure 8.1 Scanning electron micrograph of \*Leptospira\* sp. bacteria atop a 0....](#)

[Figure 8.2 \*A. aegypti\*, the mosquito vector of dengue fever. \(Image from CDC-...](#)

[Figure 8.3 Distribution of dengue, worldwide. \(From Global Burden of Disease...](#)

## Chapter 9

[Figure 9.1 Life cycle of human infection with \*T. canis\*. \(From Public Health ...](#)

[Figure 9.2 Life cycle of \*T. solium\* and cysticercosis. \(Image from CDC-PHIL \[...](#)

[Figure 9.3 Life cycle of \*T. gondii\*. \(Image from CDC-PHIL \[ID#3421\]/CDC/Alexa...](#)

[Figure 9.4 WNV, diagnosed cases and attack rate, 2012.](#)

## Chapter 10

[Figure 10.1 Global distribution of the NTDs in the decade of the 2000s. Coun...](#)

[Figure 10.2 Range of treatment costs per person per year for HIV/AIDS, tuber...](#)

[Figure 10.3 Geographic overlap of moderate to high hookworm infection preval...](#)

## Chapter 12

[Figure 12.1 Relationship between under-age-5 child mortality \(per 1,000\) and...](#)

[Figure 12.2 Telegram sent from Mikhail Chumakov to Albert Sabin regarding te...](#)

# **Forgotten People, Forgotten Diseases**

***The Neglected Tropical Diseases and  
Their Impact on Global Health and  
Development***

**Third Edition**

**PETER J. HOTEZ, MD, PHD**

Professor of Pediatrics and Molecular Virology &  
Microbiology Texas Children's Hospital Chair of Tropical  
Pediatrics National School of Tropical Medicine, Baylor  
College of Medicine Houston, Texas





**ASM  
PRESS**

WASHINGTON, DC

**WILEY**

Copyright © 2022 American Society for Microbiology. All rights reserved.

Copublication by the American Society for Microbiology and John Wiley & Sons, Inc.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted by law. Advice on how to reuse material from this title is available at <http://wiley.com/go/permissions>.

The right of Peter J. Hotez to be identified as the author of this work has been asserted in accordance with law.

*Limit of Liability/Disclaimer of Warranty*

While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties or merchantability of fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The publisher is not providing legal, medical, or other professional services. Any reference herein to any specific commercial products, procedures, or services by trade name, trademark, manufacturer, or otherwise does not constitute or imply endorsement, recommendation, or favored status by the American Society for Microbiology (ASM). The views and opinions of the author expressed in this publication do not necessarily state or reflect those of ASM, and they shall not be used to advertise or endorse any product.

*Editorial Correspondence:*

ASM Press, 1752 N Street, NW, Washington, DC 20036-2904, USA

*Registered Offices:*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products, visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

*Library of Congress Cataloging-in-Publication Data*

Names: Hotez, Peter J., author.

Title: Forgotten people, forgotten diseases : the neglected tropical diseases and their impact on global health and development / Peter J. Hotez.

Description: Third edition. | Washington, DC : ASM Press, [2022] | Series: American society for microbiology

Identifiers: LCCN 2021028002 (print) | LCCN 2021028003 (ebook) | ISBN 9781683673873 (paperback) | ISBN 9781683673880 (adobe pdf) | ISBN 9781683673897 (epub)

Subjects: LCSH: Tropical medicine.

Classification: LCC RC961 .H68 2022 (print) | LCC RC961 (ebook) | DDC  
362.196/9883-dc23

LC record available at <https://lcn.loc.gov/2021028002>

LC ebook record available at <https://lcn.loc.gov/2021028003>

Cover design by: Owen Design Company

Interior design by: Susan Brown Schmidler

Dedicated to my wife, Ann Hotez, and my four adult kids,  
Matthew Hotez, Emily Hotez, Rachel Hotez, and Daniel  
Hotez

To my mother, Jean Hotez, and brother and sister,  
Lawrence Hotes, M.D., and Elizabeth Kirshenbaum, J.D.,  
and their families

To the memory of my brother and father, Richard Hotes,  
M.D. Edward Joseph Hotez

To Mark Wallace and Paul Klotman, M.D., and the  
leadership of Texas Children's Hospital and Baylor College  
of Medicine

And to the Bill & Melinda Gates Foundation, the U.S.  
National Institutes of Health, and the Kleberg Foundation  
for the opportunity to devote my life to the Neglected  
Tropical Diseases

## Preface

Ever since junior high school, I have been fascinated by the application of scientific knowledge for solving tropical public health problems of global importance. Starting with an M.D.-Ph.D. dissertation begun in 1980, my adult life has been a quest to develop experimental vaccines for diseases of the poor, beginning with human hookworm infection. More than 20 years ago, thanks to the support of the Bill & Melinda Gates Foundation, I had the opportunity and good fortune to head a multidisciplinary team to develop and manufacture those vaccines and test them in areas of Brazil and Gabon and where hookworm was endemic. Since then our group, now co-headed by my science partner for the last 20 years, Dr. Maria Elena Bottazzi, has led the development of vaccines against schistosomiasis, Chagas disease, and other neglected tropical diseases (NTDs). Starting in 2011 we began using this same approach to develop coronavirus vaccines, including vaccines against SARS and MERS, and beginning in 2020 we turned our attention to COVID-19. As a result a new low-cost recombinant protein, COVID-19 vaccine is being scaled up for production in India, with the hope that it will fill a troubling gap in terms of COVID-19 vaccines for Africa and Latin America. While that work was intensely satisfying on both a professional and personal level, I realized that completing early-stage development of a new product for an NTD such as hookworm was in many ways the easy part! It was apparent that unless there was greater general awareness about the public health and economic importance of NTDs there would never be the political will and large-scale financial investment necessary to ensure global access to a hookworm vaccine, or indeed any other product for the diseases of poverty.



The first edition of *Forgotten People, Forgotten Diseases* focused on summarizing in mostly nontechnical language the major concepts about NTDs and how they cause human suffering, as well as their global importance and the unique and unusual opportunity we had to lift the world's poorest people out of poverty through low-cost and highly cost-effective control measures. Along with Professor David H. Molyneux of the Liverpool School of Tropical Medicine, Professor Alan Fenwick from Imperial College London, Dr. Lorenzo Savioli from the World Health Organization (as well as some of his close colleagues there, including Drs. Dirk Engels and Jacob Kumaresan), Professor Jeffrey Sachs and Dr. Sonia Ehrlich Sachs of Columbia's Earth Institute, and Dr. Eric Ottesen (then at Emory University), I formed an informal NTD working group, and in a series of policy papers published in *PLoS* and the *New England Journal of Medicine*, we were able to articulate the concept of the NTDs and how we could control or eliminate them through a global scale-up of access to essential medicines. We also established a Global Network for NTDs to coordinate global advocacy and resource mobilization efforts for these conditions.

By the time of the second edition, published in 2013, much had already begun to change. In the area of public health control in developing countries, and through support from the United States Agency for International Development (USAID), approximately 250 million people had been treated with all or part of an integrated “rapid-impact package” of essential medicines for seven of the most common NTDs—ascariasis, hookworm infection, trichuriasis, schistosomiasis, lymphatic filariasis, onchocerciasis, and trachoma. The World Health Organization estimated that more than 700 million people annually were receiving essential medicines against one or more NTDs—almost all of whom were living in the poorest

parts of Africa, Asia, and the Americas—representing some of the largest public health control efforts ever undertaken. The successes of both mass drug administration and product development activities rely heavily on a substantial alliance of private-public partnerships, including product development partnerships and nongovernmental development organizations, as well as international advocacy efforts to raise awareness about the NTDs (including the Global Network for Neglected Tropical Diseases) and parallel resource mobilization initiatives. Another major development was the realization that NTDs also occur among the poor living in wealthy countries, especially the United States and, to some extent, Europe. In 2011, I committed my life and work to this problem by relocating a group of more than a dozen scientists to Texas in order to establish the Texas Children's Hospital Center for Vaccine Development and the new National School of Tropical Medicine at Baylor College of Medicine. Through the hard work of our faculty and scientists, we uncovered an extraordinary disease burden from NTDs in Texas and adjacent Gulf Coast states, including Chagas disease, dengue, Zika virus infection, murine typhus, toxocariasis, trichomoniasis, and hookworm infection. NTDs and poverty are inextricably linked.

This third edition of *Forgotten People, Forgotten Diseases* coincides with the third decade of the NTDs movement and ecosystem that began in the early 2000s. Now mass drug administration/preventive chemotherapy is taken for granted as a recognized international standard for advancing global health and for addressing the plight of people who live in profound poverty. But this approach truly represents hard-fought efforts from our small group of tropical and parasitic disease experts, who included my “three musketeer” colleagues Alan Fenwick and David Molyneux, as well as the leaders of the WHO's Department

of NTDs Control—Lorenzo Savioli, Dirk Engels, Mwele Ntuli Malecela, and so many others.

Today, more than 1 billion people benefit from access to essential NTD medicines, and also the many collateral benefits in terms of therapeutic effects on diseases that we did not necessarily intend to target. This book tells the story of how the NTD space evolved and control was implemented on a global scale. It discusses some of the major non-governmental development organizations committed to NTDs and advocacy for the NTDs, and the important contributions of the U.S. and U.K. governments, as well as the Bill & Melinda Gates Foundation, as well as other organizations. It tells how we measured the health and economic impact of the NTDs through the Global Burden of Disease (GBD) Study of the Institute for Health Metrics and Evaluation at the University of Washington. It also highlights the role of innovation in the development of new treatments and vaccines for NTDs, and the role of important product development partnerships, including ours, and others such as DNDi, IDRI, IVI, and FIND, to name some. It explains how science and vaccine diplomacy ensures that a new generation of these biotechnologies reaches the world's poorest people. Most of all, it tells the story of the world's people who live in extreme poverty and what it means for them to live with NTDs.

PETER J. HOTEZ  
*Houston, Texas*

## Acknowledgments

This book and my career in tropical medicine owe so much, to so many people. I had the unique opportunity to thank many of them during my 2011 Presidential Address to the American Society of Tropical Medicine and Hygiene.<sup>1</sup> I again want to thank my bosses at Baylor College of Medicine and Texas Children's Hospital, Dr. Paul Klotman and Mark Wallace, respectively, and the boards of those two institutions. I also thank my long-standing colleagues and partners in battle against the neglected tropical diseases (NTDs), including Professors David Molyneux and Alan Fenwick; and Drs. Lorenzo Savioli, Dirk Engels, and Mwele Ntuli Malecela—past and current heads of the Department of Control of NTDs of the WHO. Also thanks to TDR, the Special Programme for Research and Training in Tropical Diseases, of the World Health Organization. I also thank my science partner for the last 20 years, Dr. Maria Elena Bottazzi, and our team of amazing scientists at the Texas Children's Center for Vaccine Development, and the heads and directors of the many organizations committed to NTDs, which include the areas of implementation, product development, and advocacy. Along those lines I want to thank the heads of the important non-governmental development organizations, public-private partnerships, and product development partnerships committed to the NTDs, and my good colleagues at *PLoS Neglected Tropical Diseases*. A special thank you to Drs. Patrick Soon-Shiong and Gary Michelson for their commitment and interest in NTDs. I also extend my appreciation to the work of the Institute for Health Metrics and Evaluation of the University of Washington for its Global Burden of Disease

Study (GBD) 2019. This book presents the results and mapping from the GBD 2019 for each of the major NTDs. I also want to thank Alyssa Milano for her long-standing commitment to NTDs and both Alyssa and Soledad O'Brien for their willingness to contribute forewords for the previous two editions. Many thanks to Nathaniel Wolf for his editorial assistance and insights and to Ashish Damania for his help with new maps and other related materials. I also thank Douglas Soriano Osejo for his help. Finally, many thanks to the donors and partners that made it possible for me to pursue a career in NTDs, including the Bill & Melinda Gates Foundation, the U.S. National Institutes of Health (especially the National Institute of Allergy and Infectious Diseases and the Fogarty International Center), the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, the Carlos Slim Foundation, JPB Foundation, Tito's Vodka, Southwest Electronic Energy Medical Research Institute, Blavatnik Charitable Trust, Rebecca Marvil and Brian Smyth, Mendell Family Fund, MD Anderson Foundation, Rawley Foundation, John S. Dunn Foundation, Jay H. Newman and Newman Family Foundation, Jerold B. Katz Foundation, Jesse W. Couch Charitable Foundation, and others. Finally, I want to thank my wife Ann Hotez and my family for bearing with me through another edition of *Forgotten People, Forgotten Diseases*, and Christine Charlip for “rolling the dice” once again with me at ASM Press.

PETER J. HOTEZ  
Houston, Texas

## **Note**



**1.** **Hotez PJ.** 2012. ASTMH Presidential Address. Four Horsemen of the Apocalypse. *Am J Trop Med Hyg* **87**: 3-10.

# **1 Introduction to the Neglected Tropical Diseases: the Ancient Afflictions of Stigma and Poverty**

*The age of hypocrisy has been succeeded by that of indifference, which is worse, for indifference corrupts and appeases: it kills the spirit before it kills the body. It has been stated before, it bears repeating: the opposite of love is not hate, but indifference.*

ELIE WIESEL, *A JEW TODAY*, P. 17

*It is a trite saying that one half the world knows not how the other lives. Who can say what sores might be healed, what hurts solved, were the doings of each half of the world's inhabitants understood and appreciated by the other?*

MAHATMA GANDHI

Since the beginning of the 21st century, we have seen unfold a new sense of urgency about the plight of the world's poorest people in developing countries. Today, the average well-educated layperson living in “the North” (North America, Europe, and Japan) is far more aware than ever before about the suffering of the people living in “the South” (the developing countries of sub-Saharan Africa, Asia, and the Americas). Almost certainly, the human catastrophe of HIV/AIDS in sub-Saharan Africa, known as the “plague of the 21st century,” and epidemics or pandemics from Ebola virus and Zika virus infections, and most recently coronavirus disease 2019 (COVID-19), have helped to focus world attention on health threats from infectious diseases, especially problems in the world's low- and middle-income countries (LMICs).<sup>1</sup>

Simultaneously, an unprecedented and extraordinary advocacy effort led by some highly influential international leaders and celebrities has helped to fuel a 21st-century global health movement. Throughout the decade of the 2000s, Bono, Angelina Jolie, Brad Pitt, George Clooney, Oprah Winfrey, Annie Lennox, Bob Geldof, and other actors, celebrities, and musicians; Bill Gates, Melinda French Gates, Warren Buffett, Carlos Slim and his family, and other philanthropists; Jeffrey Sachs; Chelsea Clinton; Prime Ministers Tony Blair, Gordon Brown, David Cameron, Theresa May, and Boris Johnson of the United Kingdom; and Secretaries of State Hillary Clinton and John Kerry and Presidents Jimmy Carter, Bill Clinton, George W. Bush, and Barack Obama of the United States have donated their time and energy to advocate for the health of the world's poorest people. These efforts captivated world attention and have even infused an element of glamour into solving global health problems. Between 2005 and 2006 alone, Bono, Bill Gates, and Melinda Gates were named *Time* magazine Persons of the Year; the Time Global Health Summit in New York was branded the “Woodstock of global health”; Brad Pitt narrated a 6-hour-long documentary, *Rx for Survival, a Global Health Challenge*, for PBS; former President Clinton featured global health issues at his annual Clinton Global Initiative; and Bono and Bobby Shriver launched Product RED to support HIV/AIDS, malaria, and tuberculosis relief at the 2006 World Economic Forum in Davos, Switzerland.

As a university professor and now as a dean, I can attest that these activities stimulated an unprecedented level of interest in global health issues from both undergraduates and graduate public health and medical students. With the important exception of our 2020–2021 years of COVID-19, almost every week during the academic year I have been visited by one or more young persons who request advice on how they can help solve a health problem in an LMIC. I

am not the only faculty member to have this experience—today, new university-wide global health institutes are springing up at Duke, Baylor, Brown, Yale, Vanderbilt, Harvard, Emory, Washington University in St. Louis, the University of California campuses, University of Washington, and elsewhere, as university deans and presidents scramble to keep up with student interest.

Like any movement, the one in global health that I benchmark as beginning in 2000 was stimulated by a *manifesto*, which is defined by Webster as “a public declaration of motives and intentions by a government or by a person or group regarded as having some public importance.”<sup>1</sup> For the global health movement, we can point to at least three landmark 21st-century policy documents that have effectively served as manifestos.

The first had its origins in January 2000, when then-World Health Organization (WHO) Director-General Gro Harlem Brundtland launched the Commission on Macroeconomics and Health (CMH) and appointed the international macroeconomist Jeffrey Sachs to serve as its chair. Jeff and his colleagues were charged with analyzing the impact of health on development. Their *Report of the CMH*, illustrated with examples of how health investments translate into economic development, elegantly articulated a profound relationship between disease and chronic poverty. As a result, the world's most influential finance ministers and policymakers began to regard improvements in global health as an important tool for poverty reduction. A second initiative was also launched in 2000 when the General Assembly of the United Nations convened in New York City to adopt a resolution known as the UN Millennium Declaration. The Declaration was a renewed call for sustainable development and for the eradication of poverty, and its core was a set of eight specific Millennium Development Goals (MDGs) along with a set of specific

targets for the year 2015. As shown in [Table 1.1](#), three of the goals (MDGs 4, 5, and 6) specifically emphasize health. Finally, a third manifesto was *Our Common Interest: Report of the Commission for Africa*, commissioned by British Prime Minister Tony Blair to provide specific recommendations on how to accelerate development and reduce poverty in Africa. The report served as an important blueprint for commitments by the Group of Eight (G8) nations at their 2005 summit in Gleneagles, Scotland.

**Table 1.1** The MDGs

1. Eradicate extreme poverty and hunger
2. Achieve universal primary education
3. Promote gender equality and empower women
4. Reduce child mortality
5. Improve maternal health
6. Combat HIV/AIDS, malaria, and other diseases
7. Ensure environmental sustainability
8. Develop a global partnership for development



Unlike many UN and international declarations, which too often are forgotten by the global community almost as soon as they are written, the CMH report, the MDGs, and the *Report of the Commission for Africa* continue to exert a major influence on global policymakers. Although the MDGs ended in 2015, they have since continued under a new set of Sustainable Development Goals (SDGs), sometimes just referred to as the “Global Goals”. Equally important, together with the new advocacy by leaders and celebrities, the global health manifestos have stimulated high-level efforts to invent innovative financial instruments for supporting disease control, including some very substantial funding initiatives from both the G7 nations and some prominent private philanthropic organizations such as the Bill & Melinda Gates Foundation.

MDG 6 (to “combat HIV/AIDS, malaria, and other diseases”) has been a particular target of these new funds, with approximately US\$90 billion committed so far by the U.S. Congress for HIV/AIDS through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR),<sup>2</sup> together with more than US\$6 billion for malaria through the U.S. President's Malaria Initiative (PMI). Internationally, the Global Fund to Fight AIDS, Tuberculosis, and Malaria now commits more than US\$4 billion annually to support interventions against these infections (<http://theglobalfund.org>), while the Gates Foundation has also committed vast sums. Practically speaking, these extraordinary new financial commitments mean that unprecedented numbers of poor people in Africa and elsewhere are receiving lifesaving antiretroviral medications for the treatment of HIV/AIDS or drugs and bed nets for the treatment and prevention of malaria. Such interventions are producing significant positive changes to the global health landscape under the auspices of the SDGs.

Unfortunately, with the exception of some important support from the Gates Foundation, the flurry of global health advocacy and resource mobilization occurring over the past few years has, until recently, largely bypassed the third, “other diseases” component of the original MDG 6. This neglect is particularly true for a group of exotic-sounding tropical infections that represent a health and socioeconomic problem of extraordinary dimensions but one that world leaders and global health advocates are only now waking up to. Beginning in 2005, an original core group of the 13 major so-called neglected tropical diseases, or NTDs, was proposed,<sup>3</sup> which has since been expanded by the WHO to a list of 20 diseases and conditions ([Table 1.2](#)). They include the major parasitic worm infections of humans, such as the major soil-transmitted helminth infections, e.g., ascariasis (roundworm infection), hookworm infection, and trichuriasis (whipworm infection); and lymphatic filariasis (LF or elephantiasis), schistosomiasis (snail fever), onchocerciasis (river blindness), food-borne trematode infections (liver fluke, lung fluke, and intestinal fluke), cysticercosis, echinococcosis, and dracunculiasis (guinea worm infection). In addition, the NTDs include an important group of infections caused by single-celled protozoan parasites, such as Chagas disease, leishmaniasis, and human African trypanosomiasis (sleeping sickness). Several nonparasitic infections are also prominent, including some atypical bacterial infections, such as trachoma, yaws, and endemic treponematoses; the mycobacterial infections Buruli ulcer and leprosy; mycetoma and related fungal diseases; and selected viral infections, such as dengue and rabies. More recently, snake envenomation and ectoparasitic conditions, especially scabies, were added. Still other tropical infections can also be considered NTDs,